Physician

Magda Elkabani Melchert, MD

According to 2025 Medicare claims, Magda Melchert, MD (NPI: 1376596346) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33511-4307. Melchert is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Melchert's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 948 traditional Medicare patients, billed 218,357 HCPCS/CPT codes, and received $1,819,160 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 891 prescription claims across 204 beneficiaries totaling $4,509,720 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 24 claims. Open Payments data shows 46 records totaling $1,058. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $840,314 to $4,509,720. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,130	259,011	$2,470,463
2016	1,131	290,493	$3,031,232
2017	1,220	307,618	$3,106,625
2018	1,314	308,026	$3,667,830
2019	1,461	390,158	$3,824,260
2020	1,350	369,659	$3,428,741
2021	1,230	290,487	$3,311,772
2022	1,092	267,296	$2,625,513
2023	1,018	264,220	$2,546,193
2024	948	218,357	$1,819,160

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	146	641	$840,314
2016	158	817	$998,447
2017	168	855	$1,495,629
2018	177	784	$1,927,831
2019	173	789	$2,173,465
2020	197	879	$2,888,646
2021	206	898	$2,700,282
2022	176	740	$3,057,519
2023	191	755	$2,917,442
2024	204	891	$4,509,720

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	109	$6,444
2016	N/R	24	$536
2017	N/R	N/R	N/R
2018	N/R	33	$4,880
2019	N/R	30	$3,508
2020	N/R	50	$4,365
2021	N/R	24	$1,783
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	313	808	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	321	593	$13
96372	Injection of drug or substance under skin or into muscle	189	620	$10
36415	Insertion of needle into vein for collection of blood sample	691	1,709	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	692	1,810	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	66	1,827	$1,186,865
Jakafi	Ruxolitinib Phosphate	55	1,650	$887,027
Imbruvica	Ibrutinib	24	706	$334,477
Xtandi	Enzalutamide	25	750	$311,911
Lynparza	Olaparib	12	360	$203,791

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	46	$1,058	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Magda Elkabani Melchert, MD?

Tedicare shows public-source Medicare data for Magda Elkabani Melchert, MD (NPI 1376596346), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Magda Elkabani Melchert, MD have ACO affiliation data?

Magda Elkabani Melchert, MD is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Magda Elkabani Melchert, MD?

Magda Elkabani Melchert, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Magda Elkabani Melchert, MD have Open Payments data?

Magda Elkabani Melchert, MD has 46 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.